BioTuesdays
Feature

AD focus shifts to treating agitation/aggression

By Len Zehr After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric...

October 28, 2014
Feature

In conversation with Ron Babecoff

By Len Zehr As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix...

October 14, 2014
Feature

How Itamar Medical’s PAT signal is improving health

By Len Zehr Using an unique and innovative technology known as peripheral arterial tone (PAT), Itamar Medical (TASE:ITMR) is detecting the functioning and health of arteries through a finger sensor for the diagnosis of...

October 7, 2014
Feature

In conversation with Pivotal Therapeutics

By Len Zehr BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular disease...

September 30, 2014
Feature

Finding the origins of cancer with Rosetta Genomics

By Len Zehr Taking its name from the Rosetta Stone, which paved the way to decipher ancient Egyptian hieroglyphics, Rosetta Genomics (NASDAQ:ROSG) is unlocking the relevance of microRNA within the human genome to...

August 26, 2014
Feature

Titan implanting treatments for opioid dependence

By Len Zehr In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick...

August 19, 2014
Feature

In conversation with Jason Mitakidis

By Len Zehr As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode...

August 5, 2014
Feature

XTL hopes to begin major lupus trial next year

By Len Zehr XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are...

July 22, 2014
Feature

Medifocus readies marketing expansion of Prolieve

By Len Zehr Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or...

July 8, 2014
Feature

Response Biomedical charting turnaround story

By Len Zehr The new management team of Response Biomedical (OTCBB:RPBIF; TSX:RBM), with the strong support of its controlling shareholder, OrbiMed Advisors, has adopted an aggressive plan to drive sales and achieve...

July 1, 2014
Feature

Enrollment in Athersys stroke trial nears completion

By Len Zehr Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients...

May 27, 2014
Feature

Knight won’t rest til it bests Paladin

By Len Zehr “It is entirely the goal of Knight Therapeutics (TSX:GUD) to duplicate the success of Paladin Labs,” says president and CEO, Jonathan Ross Goodman, who turned Paladin into a premier distributor of specialty...

May 13, 2014
Feature

In conversation with Alistair Duncan

By Len Zehr As a co-founder, president and CEO of closely held viDA Therapeutics, a tissue repair company, Alistair Duncan has developed an affinity for doing biotech startups. From 1998 to 2008, he was president and...

May 6, 2014